Sex is an important factor in the response to ischemic insults in both the laboratory and the clinic. Inflammation and cell death are points where sex-specific pathways diverge in stroke, and serum estrogen level status affect the response to inflammation. The cytokine macrophage migration inhibitory factor (MIF) is detrimental in experimental stroke models in male animals. However MIF is known to have sex-specific actions on inflammation and wound healing. The role of MIF in the ischemic female brain has not been evaluated. A transient middle cerebral artery occlusion (MCAO/90 min) model was used to induce stroke in male, intact female, and ovariectomized female wildtype (WT) and MIF knockout (KO) mice. Infarct size was quantified 72 h after stroke. Protein and cytokine levels were assessed post stroke. Female MIF KO mice had significantly larger strokes compared to WT females (mean hemispheric infarct±SEM: 63%±2% versus 29%±3%; n=8; pb 0.05). Ovariectomized female MIF KO mice also had larger infarcts than ovariectomized WT littermates (70%±3% versus 47%±4%; n=11; pb 0.05). In males, however, infarct size was equivalent between MIF KO and WT mice (63%±2% versus 67%±3%; n=9; p=0.25). There were no significant differences in cytokine levels at 6 h post-infarct between mice of either genotype in brain. MIF KO females displayed more microglial activation (ionized calcium binding adaptor molecule 1 (Iba1) immunofluorescence) after stroke than did WT mice or MIF KO males. The larger infarcts in MIF KO females were associated with an early increase in mitochondrial localization of Jun activation domain-binding protein 1 (JAB1). Loss of MIF exacerbated injury in the female brain after experimental stroke, which was independent of changes in pro-inflammatory cytokine levels. This response is sex-specific, and is in part independent of physiological serum levels of estrogen.
Introduction
Each year acute stroke affects approximately 800,000 people in the U.S., with 12% of those patients dying within 1 month of stroke and a third of stroke survivors experiencing permanent disability (Roger et al., 2012) . While the incidence of stroke is higher in men than in women throughout most of the lifespan, at older ages more women than men experience strokes (Roger et al., 2012) . Estrogen (E2) is a potent neuroprotective agent in vitro and in vivo (Garcia-Segura et al., 2001; McCullough and Hurn, 2003; Stein, 2001 ). However, randomized clinical trials in postmenopausal women have not shown a benefit from chronic E2 treatment for stroke prevention (Viscoli et al., 2001; Wassertheil-Smoller et al., 2003) , in part due to issues with study design (Turtzo and McCullough, 2008) . Sex differences in stroke epidemiology and outcome cannot be explained on the basis of circulating levels of gonadal steroids alone (Du et al., 2004; Li et al., 2005; Zhang et al., 2003; Zhu et al., 2006) . Laboratory and clinical data indicate that sex (e.g., male versus female) and gonadal steroid exposure both play important roles in the response to an ischemic insult (Turtzo and McCullough, 2008, 2010) . Sex differences in ischemic sensitivity may also become more apparent when the influence of gonadal steroids are removed by gonadectomy or with senescence.
Inflammation is a point where sex pathways diverge (Ritzel et al., 2012) . A leading candidate for mediating the relationship between inflammation, E2, and sex is the cytokine macrophage migration inhibitory factor (MIF). MIF's effects are mediated via interaction with Neurobiology of Disease 54 (2013) [421] [422] [423] [424] [425] [426] [427] [428] [429] [430] [431] 
